DOCSLIB.ORG

Customs Tariff - Schedule

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels. 9903.00.00 Articles and materials that enter into the cost of manufacture or repair Free CCCT, LDCT, GPT, UST, of the following, and articles for use in the following: MT, MUST, CIAT, CT, Agricultural or horticultural elevators or conveyors; CRT, IT, NT, SLT, PT, Agricultural or horticultural machinery for soil preparation or COLT, JT, PAT, HNT, cultivation, including domestic rotary tillers and lawn or sports-ground KRT, CEUT, UAT: Free rollers, and pneumatic tires and inner tubes for use therewith; Agricultural or horticultural machines for cleaning, sorting or grading seed, grain or dried leguminous vegetables; Agricultural or horticultural machines of heading 84.33, not including mowers for lawns, parks or sports-grounds, and pneumatic tires and inner tubes for use therewith; Agricultural or horticultural machines of heading 84.36; Agricultural or horticultural mechanical appliances (whether or not hand-operated) for projecting, dispersing or spraying liquids or powders, parts thereof and pneumatic tires and inner tubes for use therewith; Air heaters and parts thereof, for orchards; Apparatus for sterilizing bulbs; Apparatus for the destruction of predatory animals by the discharge of poisonous cartridges, and poisonous cartridges therefor; Automatic bale stacking wagons, grain carts and silage wagons, and parts thereof; Automatic explosive bird-scaring devices and twin-shot cartridges therefor; Binder or baler twine of polyethylene, polypropylene, sisal or other textile fibres of the genus Agave; Carbon dioxide generators and parts thereof, to be employed in controlling the atmosphere in greenhouses or in storage plants for fresh fruit or fresh vegetables; Centrifuges for testing butterfat, milk or cream; Clippers for animals and for use on the farm; Combination excavating and transporting scrapers for use on the farm, and pneumatic tires and inner tubes for use therewith; Issued January 1, 2018 99 - 2 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9903.00.00 Combination machinery for bagging or boxing and weighing, or Continued machinery for filling, for use with fresh fruit or vegetables; Cream separators; Egg cooling cabinets and furniture therefor; Electrical bird-scaring devices which produce sounds simulating natural alarm cries of birds, not including recorders or reproducers using magnetic tape; Fanning mills; Farm or logging wagons or sleds; Forage boxes for self-loading or self-unloading trailers and semi- trailers for agricultural purposes; Front-end loader attachments or snow-blowers for tractors, for use on the farm; Fuel tanks, engines, generators, electric accumulators, switchboards and panels, and parts thereof, all for generating electricity for agricultural or horticultural purposes; Generating sets for use on the farm for farm purposes only; Grain or hay dryers; Grain roasters; Gravity discharge boxes for farm wagons; Header or swather transporters and parts thereof; Hitches and couplings for use on the farm; Hydraulic hoists for unloading vehicles, for use on the farm; Instruments, appliances and machines designed for measuring the moisture content of agricultural produce; Levellers for use on the farm and pneumatic tires and inner tubes for use therewith; Machinery for bunching or tying cut flowers, vegetables or nursery stock; Machinery for filling bottles, for use in the beverage industry; Machinery for packing fresh fruit or vegetables from the dumper, feed table, bin or hopper stage to the box or bag closing stage; Machinery for power filling, for use in the dairy industry; Milk coolers and furniture therefor; Milking machines; Plucking, scalding, washing, singeing or eviscerating machinery to be employed in the preparation of poultry; Post hole diggers; Pressure testing apparatus for determining the maturity of fruit; Pruning shears or hooks; Spraying lorries (spraying trucks) for spreading dry or liquid fertilizer or sludge for agricultural use, and pneumatic tires and inner tubes for use therewith; Sprinkle or trickle irrigation systems and parts thereof, for use on the farm or in greenhouses; Steel stanchions for confining livestock either in pens or individually; Traction ditching machines (not being ploughs) and buckets, shovels, grabs, grips, pneumatic tires and inner tubes for use therewith; Tractors powered by an internal combustion engine, not including tractors of the type used on railway station platforms, road tractors for semi-trailers or tractors of a kind for hauling logs (log skidders), and buckets, shovels, grabs, grips, bulldozer or angledozer blades, scarifiers, pneumatic tires and inner tubes for use therewith and for use on the farm; chassis fitted with engines therefor, cabs therefor, and parts and Issued January 1, 2018 99 - 3 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9903.00.00 accessories thereof, other than bumpers and bumper parts, safety seat Continued belts and suspension shock-absorbers; Windmills. 9904.00.00 Kosher goods of heading 22.04 or 22.05 that originate in Israel or -N/ACIAT:Free another CIFTA beneficiary. 9905.00.00 The following Passover products for use during the Passover Free CCCT, LDCT, GPT, UST, holiday and so marked, imported during the period beginning two MT, MUST, CIAT, CT, months before the eve of the first day of that holiday and ending on CRT, PT, COLT, JT, PAT, the last day of the holiday: HNT, KRT, CEUT, UAT: Free Cake mix, pancake mix and baked goods; Canned fish and fish products other than pickled herring; Canned fruits and vegetables; Chocolates, candy and gum (excluding fruit jelly candy and jelly rings, chocolate-covered jellies, chocolate-covered marshmallows, and chocolate-covered orange peels); Dried apples; Grapeseed oil; Jam; Jelly powders and puddings; Juices (except apple juice) and juice blends (not containing apple juice); Matzo and matzo products; Margarine of tariff item No. 1517.10.10, not exceeding 50,000 kg each Passover holiday; Olives; Potato chips; Salad dressings and ketchup; Soups (including borsch) and gravies; Tomato ketchup, paste, purée and sauce; Vegetable shortening; and Vinegar. Under this Act, the Governor in Council may amend the above list of products. 9906.00.00 Foodstuffs and other consumable goods, other than alcoholic Free CCCT, LDCT, GPT, UST, beverages and tobacco products, imported for exclusive use in carrying MT, MUST, CIAT, CT, out field studies by an expedition conducted or sponsored by a CRT, IT, NT, SLT, PT, scientific or cultural organization, an institution of learning or a foreign COLT, JT, PAT, HNT, government, the participants in which are non-residents of Canada and KRT, CEUT, UAT: Free the conductees or sponsors of which have undertaken to make available to the Government of Canada all information obtained in Canada as a result of the expedition's field studies. 9907.00.00 Goods of Chapter 20, except tariff item Nos. 2001.10.00, 2001.90.10, Free AUT, NZT, CCCT, LDCT, 2006.00.10, 2008.60.90, 2008.99.40 and 2008.99.90, to be employed in the GPT, UST, MT, CIAT, CT, processing (other than packaging) of food products or beverages; CRT, IT, NT, SLT, PT, Goods of tariff item No. 2106.10.00, 2106.90.29 or 2106.90.99 to be COLT, JT, PAT, HNT, employed in the processing (other than packaging) of food products or KRT, CEUT, UAT: Free beverages Issued January 1, 2018 99 - 4 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9908.00.00 Utility vehicles of heading 87.03 and lorries (trucks) or shuttle cars of Free CCCT, LDCT, GPT, UST, heading 87.04, for use underground in mining or in developing mineral MT, MUST, CIAT, CT, deposits; CRT,
Recommended publications
  • Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal

    Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal

    testinal & in D o i tr g s e Journal of Gastrointestinal & a s t G i v f e o Narayanan et al., J Gastrointest Dig Syst 2018, 8:1 S l y a s n r ISSN: 2161-069Xt Digestive System DOI: 10.4172/2161-069X.1000553 e u m o J Research Article Open Access Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal- related Symptoms of Functional Dyspepsia Varsha Narayanan*, Amit Bhargava and Shailesh Pallewar 1Department of Medical Services and Research, Lupin Ltd., India *Corresponding author: Narayanan V, Department of Medical Services and Research, Lupin Ltd., Mumbai, India, Tel: +912266402222; E-mail: [email protected] Received date: February 09, 2018; Accepted date: February 21, 2018; Published date: February 27, 2018 Copyright: © 2018 Narayanan V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Functional Dyspepsia (FD) is a highly prevalent clinical condition that imposes negative economic burden on health-care system as well as greatly impairs quality of life. Treatment of non-specific and bothersome meal-related FD symptoms like post-prandial fullness, upper abdominal bloating and early satiety, is a therapeutic challenge for the clinicians as poorly-defined and ill-understood pathogenesis has hampered efforts to develop effective treatments. Acotiamide is first-in-class drug that exerts its gastro-kinetic effect by enhancing acetylcholine release. Though evidence of its efficacy and tolerance are available through randomized clinical trials, real world data from its regular in-clinic use is lacking.
  • Ep 2492268 A1

    Ep 2492268 A1

    (19) & (11) EP 2 492 268 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.08.2012 Bulletin 2012/35 C07D 407/10 (2006.01) A61K 31/405 (2006.01) (21) Application number: 12168896.4 (22) Date of filing: 20.07.2007 (84) Designated Contracting States: • Wynne, Graham Michael AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Abingdon, Oxfordshire OX14 4RY (GB) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Dorgan, Colin Richard SI SK TR Abingdon, Oxfordshire OX14 4RY (GB) Designated Extension States: • Johnson, Peter David AL BA HR MK RS Abingdon, oxfordshire OX14 4RY (GB) (30) Priority: 22.07.2006 GB 0614608 (74) Representative: Hollywood, Jane Constance 04.12.2006 GB 0624176 Kilburn & Strode LLP 20 Red Lion Street (62) Document number(s) of the earlier application(s) in London WC1R 4PJ (GB) accordance with Art. 76 EPC: 07766323.5 / 2 046 740 Remarks: This application was filed on 22-04-2012 as a (71) Applicant: Oxagen Limited divisional application to the application mentioned Oxfordshire OX14 4RY (GB) under INID code 62. (72) Inventors: • Armer, Richard Edward Abingdon, Oxfordshire OX14 4RY (GB) (54) Compounds having CRTH2 antagonist activity (57) Compounds of general formula (1) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically ac- ceptable salts, hydrates, solvates, complexes or prod- rugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, aller- gic rhinitis and atopic dermatitis. EP 2 492 268 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 492 268 A1 Description [0001] The present invention relates to compounds which are useful as pharmaceuticals, to methods for preparing these compounds, compositions containing them and their use in the treatment and prevention of allergic diseases such 5 as asthma, allergic rhinitis and atopic dermatitis and other inflammatory diseases mediated by prostaglandin D 2 (PGD2) or other agonists acting at the CRTH2 receptor on cells including eosinophils, basophils and Th2 lymphocytes.
  • PN0496-Acotiamide.Pdf

    PN0496-Acotiamide.Pdf

    Acotiamide hydrochloride hydrate (Acofide®) 盐酸阿考替胺 Z-338 in Zeria; YM-443 in Astellas Tablet, oral, EQ 100 mg acotiamide Acotiamide is a peripheral acetylcholinesterase inhibitor, indicated for the treatment of functional dyspepsia (FD), which was first-in-class drug to treat FD in the world and approved in 2013 by Japan PMDA. It was originally discovered by Zeria, and co-developed with Astellas. The drug is co-marketing in Japan with a single brand name. The human recommended starting dose is 100 mg at a time, and 3 times a day before meals. Worldwide Key Approvals Global Sales ($Million) Key Substance Patent Expiration 2016-May (US5981557A) 2016-May (EP0870765B1) 2013-Mar (JP) Not available 2021-May (JP3181919B2) 2016-May (CN1063442C) Mechanism of Action Acotiamide hydrochloride hydrate is an acetylcholinesterase (AChE) inhibitor and enhanced the acetylcholine (ACh)-induced contraction and motility of the gastric antrum and the gastric body. Target Binding Selectivity In vitro Efficacy In vivo Efficacy Mixed pattern: Ki1= 0.61 µM Effect dose of contraction in gastric sample: Significantly improved the gastrointestinal motility: Ki2= 2.7 µM ACh-induced: at 1 µM In normal and gastric hypomotility dogs: at 10 mg/kg. Inhibition: IC50= 3 µM Electrical-induced: at 0.3 µM In gastric hypomotility rats: at 100 mg/kg. Pharmacokinetics Parameters Rats Dogs Healthy Humans 3 10 3 10 50 mg 100 mg 200 mg 400 mg 800 mg Dose (mg/kg) (i.v.) (p.o.) (i.v.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) Tmax (hr) - 0.08 - 0.5 2.75 2.42 2.08 2.25 2.13 Cmax
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • TARIF DES DOUANES - ANNEXE 99 - I

    TARIF DES DOUANES - ANNEXE 99 - I

    TARIF DES DOUANES - ANNEXE 99 - i Chapitre 99 DISPOSITIONS DE CLASSIFICATION SPÉCIALE - COMMERCIALES Notes. 1. Les dispositions du présent Chapitre ne sont pas régies par la règle de spécificité de la Règle générale interprétative 3 a). 2. Les marchandises qui peuvent être classées dans les dispositions du Chapitre 99, sont classées dans le Chapitre 98 si elles peuvent également être classées dans ce chapitre. 3. Les marchandises peuvent être classées dans un numéro tarifaire du présent Chapitre et peuvent bénéficier des taux de droits de douane du tarif de la nation la plus favorisée ou du tarif de préférence prévus au présent Chapitre qui s’appliquent à ces marchandises selon le traitement tarifaire applicable selon le pays d’origine, mais ce classement est subordonné au classement préalable de celles-ci dans un numéro tarifaire des Chapitres 1 à 97 et à l’observation des conditions prévues par les textes d’application qui leurs sont applicables. 4. Les termes utilisés dans ce Chapitre et dans les Chapitres 1 à 97 s’entendent au sens de ces derniers Chapitres. Émis 1 janvier 2018 99 - 1 TARIF DES DOUANES - ANNEXE Numéro Unité Tarif de la Tarif de préférence SS Dénomination des marchandises tarifaire de mes. N.P.F. applicable 9901.00.00 Articles et matières devant servir à la fabrication ou à la réparation des En fr. TPAC, TPMD, TPG, produits suivants devant être utilisés dans la pêche commerciale ou TÉU, TM, TMÉU, TACI, dans la récolte commerciale de plantes aquatiques : TC, TCR, TI, TN, TSL, TP, TCOL, TJ, TPA, Appâts artificiels; TNH, TKR, TCUE, TUA : En fr.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Aryloxime Aryloximes Aryloxymes

    Aryloxime Aryloximes Aryloxymes

    (19) TZZ___¥_T (11) EP 1 511 737 B1 (12) EUROPÄISCHE PATENTSCHRIFT (45) Veröffentlichungstag und Bekanntmachung des (51) Int Cl.: Hinweises auf die Patenterteilung: C07D 237/04 (2006.01) C07D 401/12 (2006.01) 17.02.2010 Patentblatt 2010/07 A61K 31/50 (2006.01) A61P 37/00 (2006.01) (21) Anmeldenummer: 03732395.3 (86) Internationale Anmeldenummer: PCT/EP2003/005173 (22) Anmeldetag: 16.05.2003 (87) Internationale Veröffentlichungsnummer: WO 2003/104205 (18.12.2003 Gazette 2003/51) (54) ARYLOXIME ARYLOXIMES ARYLOXYMES (84) Benannte Vertragsstaaten: • BEIER, Norbert AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 64354 Reinheim (DE) HU IE IT LI LU MC NL PT RO SE SI SK TR • SCHELLING, Pierre Benannte Erstreckungsstaaten: 64367 Mühltal (DE) LT LV • WOLF, Michael 64297 Darmstadt (DE) (30) Priorität: 10.06.2002 DE 10225574 (56) Entgegenhaltungen: (43) Veröffentlichungstag der Anmeldung: WO-A-98/06704 WO-A-99/65880 09.03.2005 Patentblatt 2005/10 Bemerkungen: (73) Patentinhaber: Merck Patent GmbH Die Akte enthält technische Angaben, die nach dem 64293 Darmstadt (DE) Eingang der Anmeldung eingereicht wurden und die nicht in dieser Patentschrift enthalten sind. (72) Erfinder: • EGGENWEILER, Hans-Michael 64291 Darmstadt (DE) Anmerkung: Innerhalb von neun Monaten nach Bekanntmachung des Hinweises auf die Erteilung des europäischen Patents im Europäischen Patentblatt kann jedermann nach Maßgabe der Ausführungsordnung beim Europäischen Patentamt gegen dieses Patent Einspruch einlegen. Der Einspruch gilt erst als eingelegt, wenn die Einspruchsgebühr entrichtet
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology

    Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology

    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).